ARCA biopharma Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
26.00
12.00
19.00
24.00
27.00
22
Gross Income
26.00
12.00
19.00
24.00
27.00
22
SG&A Expense
6,914.00
9,681.00
11,436.00
16,589.00
18,685.00
8,096
EBIT
6,940.00
9,693.00
11,455.00
16,613.00
18,712.00
8,118
Non Operating Income/Expense
4.00
3.00
4.00
-
6.00
8
Pretax Income
6,939.00
9,689.00
11,445.00
16,444.00
18,551.00
7,964
Income Tax
-
-
-
-
61.00
31
Consolidated Net Income
6,939.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
Net Income
6,939.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
Net Income After Extraordinaries
6,939.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
Net Income Available to Common
8,965.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
EPS (Basic)
7.27
3.31
1.82
1.81
1.77
10.31
Basic Shares Outstanding
1,232.80
2,928.70
6,289.30
9,067.40
10,431.40
769.40
EPS (Diluted)
7.27
3.31
1.82
1.81
1.77
10.31
Diluted Shares Outstanding
1,232.80
2,928.70
6,289.30
9,067.40
10,431.40
769.40
EBITDA
6,914.00
9,681.00
11,436.00
16,589.00
18,685.00
8,096
Non-Operating Interest Income
5.00
7.00
14.00
169.00
167.00
162
Preferred Dividends
2,026.00
-
-
-
-
-
About ARCA biopharma
View Profile
